Sat, 31 Jul 2021

Mumbai (Maharashtra) [India], June 25 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd (Glenmark) has received tentative approval by the United States FoodDrug Administration (U.S. FDA) for Nintedanib Capsules, 100 mg and 150 mg, the generic version of Ofevreg;1 Capsules, 100 mg and 150 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

According to IQVIAtrade;sales data for the 12 month period ending April 2021, the Ofevreg;Capsules, 100 mg and 150 mg market2 achieved annual sales of approximately $1.6 billion.

Glenmark's current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

Sign up for Bombay News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!